Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
41
self-reported 11–50 band
Founded
1991
35 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
None on record
Company type
Nonprofit
self-reported
Description
Gastro-Intestinal (GI) cancer is the most common form of cancer in Australia. It affects more than 37,500 Australians each year and claims 50 lives every day. GI cancer includes cancers of the digestive system – oesophagus, stomach, liver, gallbladder and biliary tract, pancreas, large and small bowel, rectum and anus. Despite its prevalence, survival rates remain low: the chance of surviving five years after diagnosis is just 50%.
We’re working to change that.
By uniting a diverse network of brilliant clinicians, researchers, and community advocates, we deliver clinical trials that lead to better treatments, improved quality of life, and longer survival. Since 1991, we’ve conducted 90 research studies, giving more than 9,930 people access to promising new treatments, faster.
Clinical trials are how progress happens. They test whether new treatments work better than the current standard of care, and they’re essential to ensuring new therapies are safe, effective, and ready to be used more widely.
For patients, clinical trials can offer immediate access to the latest treatments and often improve both outcomes and quality of life. Running trials here in Australia means people can benefit from these advances up to five years earlier than if the trials were held overseas.
Specialties
All 13 specialties
- Gastro-Intestinal cancer research
- Clinical trials
- Raise awareness
- Save lives
- Pancreas
- Bowel
- Liver
- Oesophagus
- Stomach
- Cancer
- Gall Bladder
- AGITG
- cholangiocarcinoma
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU119 Missenden Rd; Sydney, New South WalesPrimary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
How many people work at this brand?
41 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does this brand have offices?
One address on record, Australia only. Primary: 119 Missenden Rd, Sydney, New South Wales.
Has this brand raised funding?
None linked to this brand.
What does this brand list as its specialties?
13 tags on the brand's own list, among them clinical trials and cancer.
Which companies are listed alongside this brand?
Six peer profiles on record: Lachlan Kean Foundation and WARPNINE.